W. N. Wu

469 total citations
28 papers, 371 citations indexed

About

W. N. Wu is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, W. N. Wu has authored 28 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 12 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in W. N. Wu's work include Pharmacogenetics and Drug Metabolism (13 papers), Receptor Mechanisms and Signaling (6 papers) and Metabolomics and Mass Spectrometry Studies (5 papers). W. N. Wu is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Receptor Mechanisms and Signaling (6 papers) and Metabolomics and Mass Spectrometry Studies (5 papers). W. N. Wu collaborates with scholars based in United States. W. N. Wu's co-authors include L. A. McKown, Sam Liao, William J. Jones, Robert B. Raffa, Annick Gauthier, John A. Masucci, Gary W. Caldwell, Joseph M. Grindel, E E Codd and Allen B. Reitz and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Anesthesiology and Drug Metabolism and Disposition.

In The Last Decade

W. N. Wu

27 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. N. Wu United States 11 162 109 64 63 54 28 371
L. A. McKown United States 12 162 1.0× 116 1.1× 110 1.7× 71 1.1× 53 1.0× 38 465
Michael C. Savides United States 7 76 0.5× 146 1.3× 31 0.5× 50 0.8× 11 0.2× 10 309
R Hurkmans Belgium 9 40 0.2× 80 0.7× 74 1.2× 54 0.9× 86 1.6× 12 331
T. W. Guentert Switzerland 15 26 0.2× 157 1.4× 71 1.1× 233 3.7× 14 0.3× 28 517
Carina Norsten‐Höög Sweden 9 34 0.2× 46 0.4× 69 1.1× 42 0.7× 54 1.0× 14 417
Natália Valadares de Moraes Brazil 11 37 0.2× 100 0.9× 37 0.6× 74 1.2× 47 0.9× 53 355
Paul Mazel United States 16 23 0.1× 210 1.9× 158 2.5× 47 0.7× 68 1.3× 27 595
Emma Gordon United States 7 43 0.3× 55 0.5× 39 0.6× 63 1.0× 192 3.6× 14 350
Timothy J. Kropp United States 5 26 0.2× 41 0.4× 79 1.2× 80 1.3× 114 2.1× 8 399
Ivan Ricordel France 13 17 0.1× 30 0.3× 84 1.3× 97 1.5× 49 0.9× 33 527

Countries citing papers authored by W. N. Wu

Since Specialization
Citations

This map shows the geographic impact of W. N. Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. N. Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. N. Wu more than expected).

Fields of papers citing papers by W. N. Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. N. Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. N. Wu. The network helps show where W. N. Wu may publish in the future.

Co-authorship network of co-authors of W. N. Wu

This figure shows the co-authorship network connecting the top 25 collaborators of W. N. Wu. A scholar is included among the top collaborators of W. N. Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. N. Wu. W. N. Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, W. N., L. A. McKown, E E Codd, & Robert B. Raffa. (2006). Metabolism of two analgesic agents, tramadol-n-oxide and tramadol, in specific pathogen-free and axenic mice. Xenobiotica. 36(6). 551–565. 7 indexed citations
2.
Wu, W. N., L. A. McKown, & Gee‐Hong Kuo. (2006). Hepatic metabolism of two α-1A-adrenergic receptor antagonists, phthalimide-phenylpiperazine analogs (RWJ-69205 and RWJ-69471), in the rat, dog and human. European Journal of Drug Metabolism and Pharmacokinetics. 31(4). 271–276. 2 indexed citations
3.
Codd, E E, John R. Carson, Raymond W. Colburn, et al.. (2006). The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216. Journal of Pharmacology and Experimental Therapeutics. 318(3). 1273–1279. 14 indexed citations
4.
Caldwell, Gary W., W. N. Wu, John A. Masucci, et al.. (2005). Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans. European Journal of Drug Metabolism and Pharmacokinetics. 30(3). 151–164. 22 indexed citations
5.
Wu, W. N., L. A. McKown, & Gee‐Hong Kuo. (2005). Metabolism of the new α-1A-adrenergic receptor antagonist, phthalimide-phenylpiperazine analog (RWJ-69442), in rat, dog and human hepatic S9 fractions, and in rats. European Journal of Drug Metabolism and Pharmacokinetics. 30(1-2). 113–120. 3 indexed citations
6.
Wu, W. N., et al.. (2004). Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin®) in animals and humans. Xenobiotica. 34(6). 591–606. 3 indexed citations
7.
Wu, W. N., L. A. McKown, & Allen B. Reitz. (2004). Human hepatic metabolism of the anxiolytic agent, RWJ-51521 — API-MS/MS identification of metabolites. European Journal of Drug Metabolism and Pharmacokinetics. 29(4). 257–262. 1 indexed citations
8.
Wu, W. N., L. A. McKown, & Allen B. Reitz. (2004). Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans. European Journal of Drug Metabolism and Pharmacokinetics. 29(4). 263–268. 2 indexed citations
9.
Yan, Zhengyin, Gary W. Caldwell, W. N. Wu, et al.. (2002). In vitroidentification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica. 32(11). 949–962. 11 indexed citations
10.
Wu, W. N., Gary W. Caldwell, & John A. Masucci. (2002). Evaluation of the excretion and metabolism of the new analgesic agent RWJ-22757 in male and female CR Wistar rats. Journal of Pharmaceutical and Biomedical Analysis. 28(3-4). 659–671.
11.
Wu, W. N., L. A. McKown, & Sam Liao. (2002). Metabolism of the analgesic drug ULTRAM ® (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica. 32(5). 411–425. 98 indexed citations
12.
Caldwell, Gary W., W. N. Wu, & John A. Masucci. (2001). Evaluation of the absorption, excretion and metabolism of [14 C] etoperidone in man. Xenobiotica. 31(11). 823–839. 6 indexed citations
13.
Wu, W. N., L. A. McKown, Annick Gauthier, William J. Jones, & Robert B. Raffa. (2001). Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica. 31(7). 423–441. 77 indexed citations
14.
Wu, W. N. & L. A. McKown. (2000). Recent Advances in Biotransformation of CNS and Cardiovascular Agents. Current Drug Metabolism. 1(3). 255–270. 12 indexed citations
15.
Wu, W. N., et al.. (1999). In vitro metabolic products of RWJ-34130, an antiarrythmic agent, in rat liver preparations. Journal of Pharmaceutical and Biomedical Analysis. 20(4). 687–695. 5 indexed citations
16.
17.
Wu, W. N., John A. Masucci, Gary W. Caldwell, & John R. Carson. (1998). Excretion and metabolism of the antihypertensive agent, RWJ-26240 (McN-5691) in dogs.. PubMed. 26(2). 115–25. 4 indexed citations
18.
Wu, W. N., et al.. (1994). Metabolism of xilobam in laboratory animals and man. Xenobiotica. 24(7). 649–662. 2 indexed citations
19.
Wu, W. N., et al.. (1992). Disposition of bepridil in laboratory animals and man. Xenobiotica. 22(2). 153–169. 11 indexed citations
20.
Wu, W. N., et al.. (1988). Metabolism of bepridil in laboratory animals and humans.. Drug Metabolism and Disposition. 16(1). 69–77. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. A. McKown Breakdown of academic impact, for papers by Michael C. Savides Breakdown of academic impact, for papers by R Hurkmans Breakdown of academic impact, for papers by T. W. Guentert Breakdown of academic impact, for papers by Carina Norsten‐Höög Breakdown of academic impact, for papers by Natália Valadares de Moraes Breakdown of academic impact, for papers by Paul Mazel Breakdown of academic impact, for papers by Emma Gordon Breakdown of academic impact, for papers by Timothy J. Kropp Breakdown of academic impact, for papers by Ivan Ricordel
Rankless by CCL
2026